Marton Horvath

Marton Horvath

Auto-generated profile, based on publicly available information

Marton Horvath

Department of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2026 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
ABAnna Bång-Rudenstam
Anna Bång-Rudenstam
MCMyriam Cerezo-Magaña
Myriam Cerezo-Magaña
MHMarton Horvath
Marton Horvath
HTHugo Talbot
Hugo Talbot
EGEmma Gustafsson
Emma Gustafsson
MBMattias Belting
Mattias Belting
Aggressive tumours are defined by microenvironmental stress adaptation and metabolic reprogramming. Within this niche, lipid droplet accumulation has emerged as a key strategy to buffer toxic lipids and suppress ferroptosis. Lipid droplet formation can occur via de novo lipogenesis or extracellular lipid-scavenging. However, how tumour cells coordinate these processes remains poorly understood. Here we identify a chondroitin sulfate (CS)-enriched glycocalyx as a hallmark of the acidic microenvironment in glioblastoma and central nervous system metastases. This CS-rich glycocalyx encapsulates tumour cells, limits lipid particle uptake and protects against lipid-induced ferroptosis. Mechanistically, we demonstrate that converging hypoxia-inducible factor and transforming growth factor beta signalling induces a glycan switch on syndecan-1—replacing heparan sulfate with CS—thereby impairing its lipid-scavenging function. Dual inhibition of CS biosynthesis and diacylglycerol O -acyltransferase-1, a critical enzyme in lipid droplet formation, triggers catastrophic lipid peroxidation and ferroptotic cell death. These findings define glycan remodelling as a core determinant of metabolic plasticity, positioning the dynamic glycocalyx as a master regulator of nutrient access, ferroptotic sensitivity and therapeutic vulnerability in cancer.